An Ireland-based clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, Iterum Therapeutics Plc (ITRM:NASDAQ), yesterday announced "the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 1 clinical trial in uncomplicated urinary tract infections (uUTI)."
The firm describes sulopenem as "a novel penem anti-infective compound with oral and IV formulations that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics."
The company indicated that the SURE 1 study is a multi-center, double-blind clinical trial instituted to measure the efficacy, tolerability and safety of oral sulopenem/probenecid for the treatment of uUTI in adult women. Patients in the study are randomized to receive either oral sulopenem/probenecid or oral ciprofloxacin, the current standard of treatment.
Iterum Therapeutics' CEO Corey Fishman commented, "We are pleased to announce the completion of enrollment in our final phase 3 trial for uncomplicated urinary tract infections (uUTI) with over 1,670 patients treated. Topline results from this trial are expected in the first quarter of 2020...It has been over 20 years since a new, oral treatment has been developed for urinary tract infections and the existing orals are no longer effective. If approved, oral sulopenem will provide an option to those patients with an elevated risk for treatment failure that currently have no other alternatives."
The firm noted that there are about 13.5 million emergency room and office visits for UTI symptoms and around 21 million uUTIs annually in the U.S. The company stated that "if approved, sulopenem will help address the significant clinical and economic need for new oral antibiotics that enable the avoidance of hospitalization or facilitate early hospital discharge by providing continuity-of-care step-down therapy."
Iterum Therapeutics is headquartered in Dublin, Ireland, and is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant pathogens. The company stated that it has received Qualified Infectious Disease Product and Fast Track designations for its oral and IV formulations of sulopenem in seven indications from the FDA.
Iterum Therapeutics began the morning with a market capitalization of about $36.1 million with approximately 14.87 million outstanding shares and a short interest of around 1.90%. ITRM shares opened nearly 12% higher today at $2.72 (+$0.29, +11.93%) over yesterday's $2.43 closing price. Since the open, the firm's stock has risen substantially, trading between $2.72 and $6.47 per share. At present, the shares are trading at $5.53 (+$3.08, +125.71%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
